It’s time to clean out three option plays to make room for new strategies as the market dynamic changes. I am recommending closing out the HCA June 2017 $80 and the Molina June 2017 $55 straddles along with the Biotelemetry May 2017 $21 protective put. Aside from the individual company-related… Read More

The market’s reaction to a fourth-quarter earnings report has likely provided a trading opportunity on a microcap biotech company with a potentially explosive future. Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company specializing in drugs for gastrointestinal conditions, is making the leap from development-stage company to one with a potential… Read More

Shares of Argos Therapeutics (NSDQ: ARGS), a development stage biotech company for personalized cancer treatments, fell sharply Feb. 22 after the company announced it would halt its phase 3 trial of its Rocapuldencel-T drug in combination with Sunitinib for treating metastatic renal cell carcinoma (kidney cancer) in children. Unfortunately, the… Read More

There are risks when you’re changing the way people see and interact with their environments. Read More

You can still play big trends, if you know where to look. Read More

Shares of USA Technologies (USAT) jumped 20% Thursday after it released its second quarter earnings report. The company booked a gain of 1 cent per share instead of an expected loss of the same magnitude, which triggered an immediate buying frenzy in the stock. Since then it has pulled… Read More

Teradyne (NYSE: TER), a leading maker of semiconductor testing equipment, is less known than other semiconductor sector stocks such as Intel and Texas Instruments. But because every electronic component made needs to be tested, Teradyne plays a central role in the chip sector.  Moreover, because demand for its testing products… Read More

On Jan. 27 I issued a buy recommendation on Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company focusing on diseases and conditions of the digestive system. The company received FDA approval for its idiopathic (cause unknown) constipation drug Trulance on Jan. 19, ten days ahead of the deadline—a bullish sign. … Read More

President Trump wasted no time in increasing the potential for healthcare disruption on his first day in office. Within a few hours of being inaugurated he signed an executive order that gives the heads of federal agencies whose jurisdictions are related to Obamacare what sounds like carte blanche to reshape… Read More

We’ve added a new way to make money through disruption. Read More

Online education understandably gets a bad rap, making most people thinking of high pressure enrollment tactics, diploma bills and government intervention. You can’t really blame people for thinking that way: University of Phoenix, the largest player in online education, has been the subject of multiple investigations and Corinthian Colleges was… Read More

It’s time to take profits on Rollins Inc., a stock that seems to be stalling out, and also to clear out the options hanger in order to make room for more opportunities. Rollins . (NYSE: ROL), the global leader in pest control, has exterminated the profit blues for us since we… Read More

Web.com (NSDQ: WEB) has made a big gain over the past month, following a successful Investor Day presentation.In our December issue, Jim Pearce named the company has one of our top picks for 2016 as it refocuses on the higher end of the web development and hosting market. It’s also… Read More

As we head into 2017 we are eliminating our Special Situations portfolio and moving those stocks into our Breakthrough Tech portfolio since at this point we see no clear distinction between the two anymore. Read More

We have more good news in this edition of Breakthrough Tech Weekly:Sell Airgain (NSDQ: AIRG) for a 37% gainSell Covisint (NSDQ: COVS) for a 9.9% gain.We’re also giving updates on  Bristol Myers Squib (NYSE: BMY),  Simulations Plus (NSDQ: SLP) and Argos Therapeutics (ARGS). Here are the details:Shares of Airgain (NSDQ:… Read More

Here are six plays with powerful catalysts for major profits. Read More

When I added NVE Corp (NSDQ: NVEC) to the portfolio back on October 20th, I honestly couldn’t have timed it any better. But the share price and its valuation has run so far, so fast, I think our best bet is to take our gain and maybe come back to it later. Read More

A well-designed option strategy first reduces risk, and second delivers the potential for profits. These straddles provide four different risk-managed trades with the potential for significant profits once the underlying stocks move. Read More

With two of our portfolio holdings staring down growing competition, I’m selling them both for gains:Arista Networks (NSDQ: ANET): Up 53% since it was recommended in March.Xilinx (NSDQ: XLNX): Up 17% since recommended in June.Arista Networks is an old-school hardware company that’s benefited from the rise of cloud computing. When… Read More

This week I’ll talk about restructuring the portfolio by using option strategies for healthcare stocks where I expect rising volatility. This strategy has been successful several times recently: our 700%+ options gain with McKesson, the recent 53% gain on Texas Instruments options, the recent 22% gain on… Read More